Evidence map›Paper›PMID 32407331›Full record

ArticlePloS one2020

A pilot study of ex-vivo MRI-PDFF of donor livers for assessment of steatosis and predicting early graft dysfunction.

Sanjaya K Satapathy, Humberto C Gonzalez, Jason Vanatta, Andrew Dyer, Wesley Angel, Simonne S Nouer, Mehmet Kocak, Satish K Kedia, Yu Jiang, Ian Clark and 11 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 1 country.

Sanjaya K SatapathyDivision of Transplant Surgery, Methodist University Hospital Transplant Institute, Memphis, TN, United States of America.ORCID 0000-0003-0153-2829
Humberto C GonzalezDivision of Transplant Surgery, Methodist University Hospital Transplant Institute, Memphis, TN, United States of America.
Jason VanattaDivision of Transplant Surgery, Methodist University Hospital Transplant Institute, Memphis, TN, United States of America.ORCID 0000-0003-4777-4575
Andrew DyerDepartment of Radiology, Methodist University Hospital, Memphis, TN, United States of America.
Wesley AngelDepartment of Radiology, Methodist University Hospital, Memphis, TN, United States of America.
Simonne S NouerDepartment of Preventive Medicine, University of Tennessee Health Sciences Center, Knoxville, Tennessee, United States of America.
Mehmet KocakDepartment of Preventive Medicine, University of Tennessee Health Sciences Center, Knoxville, Tennessee, United States of America.
Satish K KediaSchool of Public Health, University of Memphis, Memphis, TN, United States of America.ORCID 0000-0002-7114-5843
Yu JiangSchool of Public Health, University of Memphis, Memphis, TN, United States of America.
Ian ClarkDepartment of Pathology, University of Tennessee Health Science Center, Memphis, TN, United States of America.
Nour YadakDepartment of Pathology, University of Tennessee Health Science Center, Memphis, TN, United States of America.
Nosratollah NezakagtooDivision of Transplant Surgery, Methodist University Hospital Transplant Institute, Memphis, TN, United States of America.
Ryan HelmickDivision of Transplant Surgery, Methodist University Hospital Transplant Institute, Memphis, TN, United States of America.
Peter HortonDivision of Transplant Surgery, Methodist University Hospital Transplant Institute, Memphis, TN, United States of America.
Luis CamposDivision of Transplant Surgery, Methodist University Hospital Transplant Institute, Memphis, TN, United States of America.
Uchenna AgbimDivision of Transplant Surgery, Methodist University Hospital Transplant Institute, Memphis, TN, United States of America.
Benedict MaliakkalDivision of Transplant Surgery, Methodist University Hospital Transplant Institute, Memphis, TN, United States of America.
Daniel MalufDivision of Transplant Surgery, Methodist University Hospital Transplant Institute, Memphis, TN, United States of America.
Satheesh NairDivision of Transplant Surgery, Methodist University Hospital Transplant Institute, Memphis, TN, United States of America.
Hollis H HalfordDepartment of Surgery, University of Tennessee Health Science Center, Memphis, TN, United States of America.
James D EasonDivision of Transplant Surgery, Methodist University Hospital Transplant Institute, Memphis, TN, United States of America.
University of Tennessee Health Science Center · USMethodist University Hospital · USUniversity of Memphis · USUniversity of Tennessee at Knoxville · USHenry Ford Health System · USNorthwell Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe utility of ex vivo Magnetic resonance imaging proton density fat fraction (MRI-PDFF) in donor liver fat quantification is unknown. PURPOSE: To evaluate the diagnostic accuracy and utility in predicting early allograft dysfunction (EAD) of ex vivo MRI-PDFF measurement of fat in deceased donor livers using histology as the gold standard.

methodsWe performed Ex vivo, 1.5 Tesla MRI-PDFF on 33 human deceased donor livers before implantation, enroute to the operating room. After the exclusion of 4 images (technical errors), 29 MRI images were evaluable. Histology was evaluable in 27 of 29 patients. EAD was defined as a peak value of aminotransferase >2000 IU/mL during the first week or an INR of ≥1.6 or bilirubin ≥10 mg/dL at day 7.

resultsMRI-PDFF values showed a strong positive correlation (Pearson's correlation coefficient) when histology (macro-steatosis) was included (r = 0.78, 95% confidence interval 0.57-0.89, p<0.0001). The correlation appeared much stronger when macro plus micro-steatosis were included (r = 0.87, 95% confidence interval 0.72-0.94, p<0.0001). EAD was noted in 7(25%) subjects. AUC (Area Under the Curve) for macro steatosis (histology) predicted EAD in 73% (95% CI: 48-99), micro plus macro steatosis in 76% (95% CI: 49-100). AUC for PDFF values predicted EAD in 67(35-98). Comparison of the ROC curves in a multivariate model revealed, adding MRI PDFF values to macro steatosis increased the ability of the model in predicting EAD (AUC: 79%, 95% CI: 59-99), and addition of macro plus micro steatosis based on histology predicted EAD even better (AUC: 90%: 79-100, P = 0.054).

conclusionIn this pilot study, MRI-PDFF imaging showed potential utility in quantifying hepatic steatosis ex-vivo donor liver evaluation and the ability to predict EAD related to severe allograft steatosis in the recipient.

Indexed as

Magnetic Resonance ImagingAgedArea Under CurveBilirubinBiomarkersFemaleHumansInternational Normalized RatioLiverLiver TransplantationMaleMiddle AgedNon-alcoholic Fatty Liver DiseasePilot ProjectsROC CurveTransaminasesBilirubinBiomarkersTransaminases

Identifiers

PMID32407331
PMCPMC7224456
OpenAlexW3024659436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.